



Inspired by patients.  
Driven by science.

## UCB, Inc. Refund Notice

UCB, Inc. (UCB) has recently recalculated 340B Ceiling Prices for the products listed in the table below for the time period of **January 1, 2023 through September 30, 2023**. As a result of the recalculated 340B Ceiling Prices, UCB has determined that, pursuant to 42 U.S.C. § 256b(d)(1)(B)(ii) and 42 C.F.R. §10.11(b)(4), a refund is or may be due to any eligible 340B Covered Entity that purchased the affected products during the specified period.

### Products/NDCs Subject to Refund

Time Period	Product Name	NDC-11
<b>1Q2023</b> <b>(1/1/2023 to 3/31/2023)</b>	<b>CIMZIA 200MG-1</b>	<b>50474-0700-62</b>
<b>2Q2023 &amp; 3Q2023</b> <b>(4/1/2023 to 9/30/2023)</b>	<b>BRIVIACT 10MG - 60</b> <b>BRIVIACT 25MG UD - 100</b> <b>BRIVIACT 25MG - 60</b> <b>BRIVIACT 50MG UD - 100</b> <b>BRIVIACT 50MG - 60</b> <b>BRIVIACT 75MG - 60</b> <b>BRIVIACT 10MG/ML ORAL SOLUTION - 300ML</b> <b>BRIVIACT IV 50MG/5ML</b> <b>CIMZIA 200MG-1</b> <b>KEPPRA 500 MG-120</b> <b>NAYZILAM 5 MG NASAL SPRAY</b> <b>NEUPRO 4MG-30</b> <b>NEUPRO 6MG-30</b> <b>NEUPRO 8MG-30</b> <b>VIMPAT 100MG-60</b> <b>VIMPAT 100MG UD-60</b> <b>VIMPAT 150MG-60</b> <b>VIMPAT 150MG UD-60</b> <b>VIMPAT 200MG-60</b> <b>VIMPAT 200MG UD-60</b> <b>VIMPAT 50MG-60</b> <b>VIMPAT 50MG UD-60</b> <b>VIMPAT 10MG/ML 200ML CV SOL US</b>	<b>50474-0370-66</b> <b>50474-0470-09</b> <b>50474-0470-66</b> <b>50474-0570-09</b> <b>50474-0570-66</b> <b>50474-0670-66</b> <b>50474-0870-15</b> <b>50474-0970-75</b> <b>50474-0700-62</b> <b>50474-0595-40</b> <b>50474-0500-15</b> <b>50474-0804-03</b> <b>50474-0805-03</b> <b>50474-0806-03</b> <b>00131-2478-35</b> <b>00131-2478-60</b> <b>00131-2479-35</b> <b>00131-2479-60</b> <b>00131-2480-35</b> <b>00131-2480-60</b> <b>00131-2477-35</b> <b>00131-2477-60</b> <b>00131-5410-70</b>



Inspired by **patients**.  
Driven by **science**.

## Refund Process - amount equal to or in excess of \$50 (aggregate for all applicable NDCs)

If your aggregated refund amount for the applicable products and time periods is equal to or in excess of \$50 of all applicable NDCs, you will be contacted directly.

- 340B Covered Entities entitled to an aggregated refund of \$50 or more will be contacted directly by or on behalf of UCB with details on the refund process.
- Questions:  
For questions or to confirm refund eligibility, contact 340B@UCB.com.

## Refund Process – amount less than \$50\* (aggregate for all applicable NDCs)

If your aggregated refund amount for the applicable products and time periods is below the threshold \$50 of all applicable NDCs, you will not be contacted directly. Instead, please follow these steps:

Initiate Contact – Send an email to 340B@UCB.com with the subject line -  
“340B Refund Request – **[Insert Time Period/Product/NDC]**”.

Provide Details – Email should include Covered Entity Name, 340B ID, relevant NDC(s), relevant time period(s), and any supporting documentation or purchase records.

Confirmation and Processing - UCB will review your request, confirm eligibility, and provide instructions for processing the refund.

Questions - For questions or to confirm refund eligibility, contact 340B@UCB.com.

\* Refunds below the threshold are not issued automatically. Covered Entities must proactively request these refunds by following the steps above.

## Transparency

UCB, Inc. has requested that the Health Resources and Services Administration (HRSA) post this notice on its public website to ensure transparency regarding the recalculation and refund process.